Isoginkgetin
Based on 20 publication(s) in Google Scholar
Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 548-19-6
- Formula: C32H22O10
- Molecular Weight:566.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Isoginkgetin
More- Mol Cell. 2025 Apr 17:S1097-2765(25)00307-7. [Abstract]
- Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
- Autophagy. 2023 Apr;19(4):1221-1238. [Abstract]
- Theranostics. 2025 Mar 18;15(10):4325-4344. [Abstract]
- Nucleic Acids Res. 2023 Aug 25;51(15):7951-7971. [Abstract]
- Nucleic Acids Res. 2023 May 22;51(9):e49. [Abstract]
- Nucleic Acids Res. 2020 Dec 16;48(22):e127. [Abstract]
- J Nanobiotechnology. 2023 Mar 21;21(1):99. [Abstract]
- J Hazard Mater. 2024 Aug 22:478:135583. [Abstract]
- Food Chem. 2025 Dec 30:497:146992. [Abstract]
- Food Chem. 2025 May 31:489:144992. [Abstract]
- EMBO Mol Med. 2025 Oct 15. [Abstract]
- Cell Rep. 2025 Dec 5;44(12):116659. [Abstract]
- J Ethnopharmacol. 2024 May 10:325:117824. [Abstract]
- RNA. 2022 Mar;28(3):303-319. [Abstract]
- Molecules. 2022 Nov 29;27(23):8335. [Abstract]
- J Biol Chem. 2021 Aug;297(2):100994. [Abstract]
- Chem Biol Drug Des. 2022 Jun;99(6):923-929. [Abstract]
- Biomed Res Int. 2020 Dec 24:2020:8887982. [Abstract]
- J Vis Exp. 2025 Jul 18:(221). [Abstract]
-
Cell Proliferation/Viability Assay
-
IF
-
Cell Proliferation/Viability Assay
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| L6 | IC50 |
11 μM
Compound: isoginkgetin
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 22989363] |
| PC-12 | EC50 |
5.18 μM
Compound: 10
|
Neuroprotective activity against 0.1 uM amyloid beta 42-induced toxicity in rat PC12 cells assessed as cell viability after 24 hrs by MTT assay
Neuroprotective activity against 0.1 uM amyloid beta 42-induced toxicity in rat PC12 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 26004578] |
Isoginkgetin (0-20 μM, 24 h) inhibits cell invasion in a dose-dependent manner[1].
Isoginkgetin (10 μM, 0-24 h) induces the accumulation of ubiquitinated protein cargo into perinuclear aggregates, activates autophagy and induces lysosomal swelling, repositioning, and acidification[2].
Isoginkgetin (10 μM, 0-6 h) induces ER stress, impairs the unfolded protein response, and results in accumulation of ERAD substrates[2].
Isoginkgetin directly inhibits the chymotrypsin-, trypsin-, and caspase-like activities of the 20S proteasome and impairs NF-κB signaling[2].
Isoginkgetin (30 μM, 0-24 h) induces apoptosis in MM cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 and B16F10
-
Concentration:0, 5, 10 and 20 μM
-
Incubation Time:24 h
-
Result:Inhibited cell invasion in a dose-dependent manner.
-
Cell Line:HeLa cells and MM cell lines (MM1S, 8826, OPM2, H929, JJN3 and U266)
-
Concentration:10 μM in HeLa cells, 30 μM in MM cell lines
-
Incubation Time:0-24 h
-
Result:Induced the expression of cleaved PARP-1 and Casp-3. Increased the protein levels of both ATF4 and ATF3. Decreased the level of LC3 I. Increased TFEB activation. Prevented the degradation of IκBα in response to stimulation with TNF-α.
-
Cell Line:MM1S, 8826, OPM2, H929, JJN3 and U266 cells
-
Concentration:
-
Incubation Time:72 h
-
Result:Inhibited cell viability with IC50 values of 3.992, 3.716, 4.749, 2.564, 3.806 and 4.147 μM against MM1S, 8826, OPM2, H929, JJN3 and U266 cells, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Kunming mice (age 8–10weeks, 30–50 g)[3]
-
Dosage:4 mg/kg
-
Administration:Daily for 14 days by intraperitoneally (i.p.) prior to LPS (0.83mg/kg) administration.
-
Result:Markedly suppressed the production of IL-1β, IL-6, tumor necrosis factor-alpha, cyclooxygenase-2, inducible nitric oxide, and reactive oxygen species.
Chemical Information
-
CAS No. 548-19-6
-
Appearance Solid
-
Molecular Weight 566.51
-
Formula C32H22O10
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=C(OC)C=C2)OC3=C(C4=CC(C5=CC(C6=C(O)C=C(O)C=C6O5)=O)=CC=C4OC)C(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell
2025 Apr 17:S1097-2765(25)00307-7. PMID: 40267921 -
Acta Pharm Sin B
Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]2021 Jan;11(1):143-155. PMID: 33532186 -
Autophagy
Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma. [Abstract]2023 Apr;19(4):1221-1238. PMID: 36048765 -
Theranostics
A natural small molecule isoginkgetin alleviates hypercholesterolemia and atherosclerosis by targeting ACLY. [Abstract]2025 Mar 18;15(10):4325-4344. PMID: 40225566 -
Nucleic Acids Res
MEN1 is a regulator of alternative splicing and prevents R-loop-induced genome instability through suppression of RNA polymerase II elongation. [Abstract]2023 Aug 25;51(15):7951-7971. PMID: 37395406 -
Nucleic Acids Res
2023 May 22;51(9):e49. PMID: 36938886 -
Nucleic Acids Res
TriTag: an integrative tool to correlate chromatin dynamics and gene expression in living cells. [Abstract]2020 Dec 16;48(22):e127. PMID: 33104788 -
J Nanobiotechnology
Isoginkgetin-loaded reactive oxygen species scavenging nanoparticles ameliorate intervertebral disc degeneration via enhancing autophagy in nucleus pulposus cells. [Abstract]2023 Mar 21;21(1):99. PMID: 36941611 -
J Hazard Mater
Identification of sanguinarine as a novel antagonist for perfluorooctanoate/perfluorooctane sulfonate-induced senescence of hepatocytes: An integrated computational and experimental analysis. [Abstract]2024 Aug 22:478:135583. PMID: 39180998 -
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 May 31:489:144992. PMID: 40466530 -
EMBO Mol Med
Isoginkgetin antagonizes ALS pathologies in its animal and patient iPSC models via PINK1-Parkin-dependent mitophagy. [Abstract]2025 Oct 15. PMID: 41094045 -
Cell Rep
circATF6 triggers calcium overload to synergize with EGFR-TKI in non-small cell lung cancer via modulation of proteostasis. [Abstract]2025 Dec 5;44(12):116659. PMID: 41351835 -
J Ethnopharmacol
Cornus officinalis var. koreana Kitam extracts alleviate cadmium-induced renal fibrosis by targeting matrix metallopeptidase 9. [Abstract]2024 May 10:325:117824. PMID: 38278375 -
RNA
Splicing efficiency of minor introns in a mouse model of SMA predominantly depends on their branchpoint sequence and can involve the contribution of major spliceosome components. [Abstract]2022 Mar;28(3):303-319. PMID: 34893560 -
Molecules
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy. [Abstract]2022 Nov 29;27(23):8335. PMID: 36500428
Isoginkgetin purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Nov 29;27(23):8335. [Abstract]
Isoginkgetin (Iso; 10, 15, 25 µM; 24, 48, 72 h) reduces the viability of U87MG in a time and dose-dependent manner.
Isoginkgetin purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Nov 29;27(23):8335. [Abstract]
Isoginkgetin (Iso; 15, 25 µM; 48 h) determines a redistribution of vimentin, which no longer appears distributed in the extensions but are thickened in a roundish shape in U87MG cells.
Isoginkgetin purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Nov 29;27(23):8335. [Abstract]
The number of colonies decreased by 38% and 57%, respectively, in U87MG treated with Isoginkgetin (Iso; 15, 25 µM; 12 days) compared to the control cells.
-
J Biol Chem
CDC5L promotes early chondrocyte differentiation and proliferation by modulating pre-mRNA splicing of SOX9, COL2A1, and WEE1. [Abstract]2021 Aug;297(2):100994. PMID: 34298017 -
Chem Biol Drug Des
Isoginkgetin inhibits inflammatory response in the fibroblast-like synoviocytes of rheumatoid arthritis by suppressing matrix metallopeptidase 9 expression. [Abstract]2022 Jun;99(6):923-929. PMID: 35353950 -
Biomed Res Int
Exploring the Antitumor Mechanisms of Zingiberis Rhizoma Combined with Coptidis Rhizoma Using a Network Pharmacology Approach. [Abstract]2020 Dec 24:2020:8887982. PMID: 33426081 -
J Vis Exp
2025 Jul 18:(221). PMID: 40758599
Solvent & Solubility
DMSO : 100 mg/mL (176.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.67 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.67 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 1.67 mg/mL (2.95 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yoon SO, et al. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol Cancer Ther. 2006 Nov;5(11):2666-75. [Content Brief]
[2]. Tsalikis J, et al. Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance. Mol Cell Biol. 2019 Apr 30;39(10):e00489-18. [Content Brief]
[3]. Li P, et al. Isoginkgetin treatment attenuated lipopolysaccharide-induced monoamine neurotransmitter deficiency and depression-like behaviors through downregulating p38/NF-κB signaling pathway and suppressing microglia-induced apoptosis. J Psychopharmacol. 2021 Oct;35(10):1285-1299. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7652 mL | 8.8260 mL | 17.6519 mL | 44.1298 mL |
| 5 mM | 0.3530 mL | 1.7652 mL | 3.5304 mL | 8.8260 mL | |
| 10 mM | 0.1765 mL | 0.8826 mL | 1.7652 mL | 4.4130 mL | |
| 15 mM | 0.1177 mL | 0.5884 mL | 1.1768 mL | 2.9420 mL | |
| 20 mM | 0.0883 mL | 0.4413 mL | 0.8826 mL | 2.2065 mL | |
| 25 mM | 0.0706 mL | 0.3530 mL | 0.7061 mL | 1.7652 mL | |
| 30 mM | 0.0588 mL | 0.2942 mL | 0.5884 mL | 1.4710 mL | |
| 40 mM | 0.0441 mL | 0.2206 mL | 0.4413 mL | 1.1032 mL | |
| 50 mM | 0.0353 mL | 0.1765 mL | 0.3530 mL | 0.8826 mL | |
| 60 mM | 0.0294 mL | 0.1471 mL | 0.2942 mL | 0.7355 mL | |
| 80 mM | 0.0221 mL | 0.1103 mL | 0.2206 mL | 0.5516 mL | |
| 100 mM | 0.0177 mL | 0.0883 mL | 0.1765 mL | 0.4413 mL |